New cancer drug trial seeks first human volunteers
NCT ID NCT05701527
Summary
This is an early-stage study to test the safety of a new drug called EBC-129 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will first test EBC-129 by itself to find a safe dose, then test it combined with an existing immunotherapy drug (pembrolizumab). The main goal is to understand the side effects and determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre Singapore
RECRUITINGSingapore, South West, 168583, Singapore
Contact
-
National University Hospital - Medical Oncology
RECRUITINGSingapore, South West, 119228, Singapore
Contact
-
Taipei Veterans General Hospital
NOT_YET_RECRUITINGTaipei, Taipei, 11217, Taiwan
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center
RECRUITINGAurora, Colorado, 80045-2517, United States
Contact
Conditions
Explore the condition pages connected to this study.